Merck & Co. Inc.'s early filing of the Keytruda/chemotherapy combination in first-line squamous lung cancer with the US FDA, based just on secondary endpoint response rate data, shows once again that the company is a step ahead of the PD-1 pack, though a close competitor – Bristol-Myers Squibb Co.'s Opdivo/Yervoy combo – also could be in the running.
Merck announced May 3 that it recently submitted an sBLA for its PD-1 inhibitor Keytruda (pembrolizumab) for use in combination with carboplatin-paclitaxel or
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?